Decompensated MASH-cirrhosis model by acute and toxic effects of phenobarbital.

dc.contributor.authorGrünewald, Inga
dc.contributor.authorKraus, Nico
dc.contributor.authorUschner, Frank Erhard
dc.contributor.authorMoeslein, Magnus
dc.contributor.authorSchierwagen, Robert
dc.contributor.authorGu, Wenyi
dc.contributor.authorBrol, Maximilian Joseph
dc.contributor.authorFürst, Eike
dc.contributor.authorLotersztajn, Sophie
dc.contributor.authorRautou, Pierre-Emmanuel
dc.contributor.authorDuran Güell, Marta
dc.contributor.authorFlores Costa, Roger
dc.contributor.authorClària i Enrich, Joan
dc.contributor.authorTrebicka, Jonel
dc.contributor.authorKlein, Sabine
dc.date.accessioned2025-04-07T08:19:08Z
dc.date.available2025-04-07T08:19:08Z
dc.date.issued2024
dc.date.updated2025-04-07T08:19:08Z
dc.description.abstractMetabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl4) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl4 intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl4 + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec756642
dc.identifier.issn2073-4409
dc.identifier.pmid39451225
dc.identifier.urihttps://hdl.handle.net/2445/220281
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cells13201707
dc.relation.ispartofCells, 2024, vol. 13, num.20
dc.relation.urihttps://doi.org/10.3390/cells13201707
dc.rightscc-by (c) Kraus N et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationMalalties del fetge
dc.subject.classificationHipercolesterolèmia
dc.subject.classificationCirrosi hepàtica
dc.subject.otherLiver diseases
dc.subject.otherHypercholesteremia
dc.subject.otherHepatic cirrhosis
dc.titleDecompensated MASH-cirrhosis model by acute and toxic effects of phenobarbital.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
886995.pdf
Mida:
30.74 MB
Format:
Adobe Portable Document Format